REPORTS

Let’s Pullulate and Expand Your Business

Kinase Inhibitors Market - Global Professional Analysis and Forecast to 2026

Oct 10, 2019  |  152 PAGES  |  REPORT CODE: CMM203637
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Kinase Inhibitors market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.5% during the forecast period.

This report presents the market size and development trends by detailing the Kinase Inhibitors market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Kinase Inhibitors market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Kinase Inhibitors industry and will help you to build a panoramic view of the industrial development.

Kinase Inhibitors Market, By Type:

  • Type 1

  • Type 2

  • Type 3

Kinase Inhibitors Market, By Application:

  • End-Users 1

  • End-Users 2

  • End-Users 3

Some of the leading players are as follows:

  • Novartis International

  • Array Biopharma

  • Takeda Pharmaceuticals

  • Sanofi-Aventis

  • Amgen

  • Roche Group

  • Eisai

  • Cytrx Corporation

  • Glaxosmithkline

  • Bayer

  • Merck Serono

  • Aveo Pharmaceuticals

  • Exelixis

  • Abbott Laboratories

  • S*Bio Pte

  • Arqule

  • Boehringer Ingelheim

  • Pfizer

  • Eton Bioscience

  • Osi Pharmaceuticals

  • Astrazeneca

  • Bristol-Myers Squibb

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Kinase Inhibitors Market: Technology Type Analysis

  • 4.1 Kinase Inhibitors Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Kinase Inhibitors Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Type 1

    • 4.3.2 Type 2

    • 4.3.3 Type 3

5 Kinase Inhibitors Market: Product Analysis

  • 5.1 Kinase Inhibitors Product Market Share Analysis, 2018 & 2026

  • 5.2 Kinase Inhibitors Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Kinase Inhibitors Market: Application Analysis

  • 6.1 Kinase Inhibitors Application Market Share Analysis, 2018 & 2026

  • 6.2 Kinase Inhibitors Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Kinase Inhibitors Market: Regional Analysis

  • 7.1 Kinase Inhibitors Regional Market Share Analysis, 2018 & 2026

  • 7.2 Kinase Inhibitors Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Novartis International

    • 9.1.1 Novartis International Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Array Biopharma

    • 9.2.1 Array Biopharma Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Takeda Pharmaceuticals

    • 9.3.1 Takeda Pharmaceuticals Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi-Aventis

    • 9.4.1 Sanofi-Aventis Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Amgen

    • 9.5.1 Amgen Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Roche Group

    • 9.6.1 Roche Group Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Eisai

    • 9.7.1 Eisai Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Cytrx Corporation

    • 9.8.1 Cytrx Corporation Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Glaxosmithkline

    • 9.9.1 Glaxosmithkline Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Bayer

    • 9.10.1 Bayer Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Merck Serono

    • 9.11.1 Merck Serono Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Aveo Pharmaceuticals

    • 9.12.1 Aveo Pharmaceuticals Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Exelixis

    • 9.13.1 Exelixis Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Abbott Laboratories

    • 9.14.1 Abbott Laboratories Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 S*Bio Pte

    • 9.15.1 S*Bio Pte Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Arqule

    • 9.16.1 Arqule Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Boehringer Ingelheim

    • 9.17.1 Boehringer Ingelheim Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Pfizer

    • 9.18.1 Pfizer Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Eton Bioscience

    • 9.19.1 Eton Bioscience Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Osi Pharmaceuticals

    • 9.20.1 Osi Pharmaceuticals Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 Astrazeneca

    • 9.21.1 Astrazeneca Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

  • 9.22 Bristol-Myers Squibb

    • 9.22.1 Bristol-Myers Squibb Company overview

    • 9.22.2 Financial performance

    • 9.22.3 Product benchmarking

    • 9.22.4 Strategic initiatives

    • 9.22.5 SWOT analysis

 

The List of Tables and Figures (Totals 82 Figures and 137 Tables)

  • Figure Type 1 Kinase Inhibitors market, 2015 - 2026 (USD Million)

  • Figure Type 2 Kinase Inhibitors market, 2015 - 2026 (USD Million)

  • Figure Type 3 Kinase Inhibitors market, 2015 - 2026 (USD Million)

  • Figure End-Users 1 market, 2015 - 2026 (USD Million)

  • Figure End-Users 2 market, 2015 - 2026 (USD Million)

  • Figure End-Users 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Kinase Inhibitors market, by country, 2015 - 2026 (USD Million)

  • Table North America Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table North America Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table North America Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Canada Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Canada Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Europe Kinase Inhibitors market, by country, 2015 - 2026 (USD Million)

  • Table Europe Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Europe Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Europe Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Germany Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Germany Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table France Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table France Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Italy Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Italy Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Spain Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Spain Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Kinase Inhibitors market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table China Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table China Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Japan Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Japan Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table India Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table India Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Kinase Inhibitors market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table MEA Kinase Inhibitors market, by country, 2015 - 2026 (USD Million)

  • Table MEA Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table MEA Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table MEA Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Kinase Inhibitors market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Kinase Inhibitors market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Kinase Inhibitors market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Novartis International Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Array Biopharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi-Aventis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Roche Group Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eisai Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Cytrx Corporation Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Glaxosmithkline Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Serono Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Aveo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Exelixis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table S*Bio Pte Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Arqule Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eton Bioscience Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Osi Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Astrazeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top